Systemic Anticancer Therapy in the Last 30 Days of Life Is Tied to More Acute Care and Less Hospice Use in Older Adults: A SEER–Medicare Analysis
Highlight
– In a SEER–Medicare cohort of 315,089 patients aged ≥66 who died 2015–2020, 7.6% received systemic anticancer therapy (SACT) within 30 days of death.
– Any SACT at end of life (EOL) was associated with markedly increased odds of emergency department visits (OR 3.05), hospital admission (OR 2.64), ICU admission (OR 1.78), and inpatient death (OR 2.02), and with lower hospice utilization (OR 0.51).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.